Innovation in the pharmaceutical industry continues to reshape how drugs and biologics are discovered, developed, and manufactured, creating scientific and regulatory issues that often surface in complex litigation. As companies navigate questions around intellectual property, clinical evidence, safety, and compliance, legal teams increasingly rely on our pharmaceutical experts to clearly explain the science and decision-making behind these products.
DOAR represents life science experts whose experience spans pharmacology, clinical development, manufacturing, and post-market safety. They are familiar with each stage of the product lifecycle—from early research and formulation through clinical trials, regulatory submissions, scale-up, and commercialization—allowing them to address matters involving product design, labeling, risk evaluation, and market performance.
In high-stakes disputes, tour testifying experts evaluate the scientific and regulatory record, test competing narratives, and present complex pharmaceutical issues in a way that judges, juries, and regulators can understand and rely on.
Contact UsWe represent experts who are world-class academics, industry executives, and former government regulators who were carefully selected for their knowledge, experience, and ability to communicate effectively.
Expertise in trial design, data analysis, and interpretation of clinical evidence used to support safety, efficacy, and regulatory decisions.
Experience evaluating safety signals, diversion risks, and counterfeit detection, including how quality and surveillance processes address product integrity.
Knowledge spanning biologics, small-molecule drugs, and OTC products, including differences in formulation, manufacturing, and regulatory pathways.
Insight into market dynamics, competitive trends, and regulatory developments that shape product strategy and commercial outcomes.
Background in patent disputes, exclusivity issues, and regulatory adherence across drug development, approval, and post-market obligations.
Experience with cGMP standards, FDA inspections, and production quality systems that affect regulatory status, recalls, and related disputes.
Understanding of labeling requirements, promotional practices, pricing strategies, and how these factors influence compliance and litigation risk.
As technology transforms what is possible in juror research, the gap between available tools and permissible practices continues to widen, particularly with respect to social media.
Using aggregated filing data from the wireless dataset, we provide a data-driven view of where litigation is concentrated, which parties are most active, and how the structure of the wireless market shapes the legal landscape.
State rules can dramatically alter what experts must disclose before trial and what they’re allowed to say during it. Let’s examine the spectrum of these guidelines and how they shift by location.
Our latest ALJ report provides a comprehensive analysis of Administrative Law Judge Bryan Moore’s activity at the ITC.
DOAR is proud to have supported the plaintiffs and their counsel at Winston & Strawn LLP in this significant victory for immigrants whose civil rights and due process protections were violated.
Research has shown that external variables can influence decision-making even for “objective” fact-finders.
As Vice President, Experts, Hamilton will be responsible for executing and evolving the strategic vision of DOAR’s expert witness practice.
New data reveals how crypto disputes are playing out in courtrooms nationwide, as the fast-evolving industry faces growing legal accountability.